You are here:

Home
NICE Guidance
Conditions and diseases
Musculoskeletal conditions
Arthritis

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis

Technology appraisal guidance
Reference number: TA199
Published: 25 August 2010

Guidance
Tools and resources
Information for the public
Evidence
History

Consultee and commentator comments on the ACD

Abbott response to PsA ACD
Pfizer Enbrel response to PsA ACD
Pfizer Enbrel pooled estimates of PASI response
Schering Plough response to PsA ACD
The Psoriasis and Psoriatic Arthritis Alliance response to PsA ACD
Royal College of Nursing response to PsA ACD
Department of Health response to PsA ACD
NHS Quality Improvement Scotland response to PsA ACD
Welsh Assembly Government response to PsA ACD
York Assessment Group response to PsA ACD

This page was last updated: 08 June 2010